Qelbree vs Strattera: Onset, Dosing, and Side Effects

If you’ve been told Qelbree works faster than Strattera, you’ve heard the most common claim about these two non-stimulant ADHD medications. But no randomized trial has ever put the two drugs side by side, and the difference that matters most for you might be a medication you already take.

Your prefrontal cortex depends on norepinephrine to hold attention and filter distractions, and a protein called the norepinephrine transporter clears that signal away once it’s sent. Both drugs slow the transporter, so more norepinephrine stays available where focus is regulated. According to the Qelbree prescribing information, viloxazine also acts as an agonist at the serotonin 5-HT2C receptor. The real question is how precisely each drug reaches that target, and what else it touches.

Atomoxetine (Strattera) has been prescribed for ADHD since 2002. Its effectiveness rests on seven clinical trials, including two 10-week studies in adults, and a 2025 BMJ umbrella review rated its evidence in adults as at least moderate certainty. The results are real, and the science is well established.

Atomoxetine is no longer the only drug that works this way, and at Siggy we’d rather show you what the trials measured than repeat a brand’s shorthand. Viloxazine extended-release (Qelbree), approved in 2021, blocks the same transporter with a different chemical structure, far less sensitivity to your genetics, and a different set of interactions. This guide compares onset, dosing, side effects, and safety, and says plainly where the evidence runs out. What separates these two drugs is far less a matter of marketing than of pharmacology.

What This Page Covers

• How Qelbree and Strattera Work
• Which Works Faster, Qelbree or Strattera?
• How Dosing Differs
• Side Effects Compared
• Drug Interactions Are the Biggest Practical Difference
• Heart Rate, Mood, and Other Safety Warnings
• What Happens When People Switch?
• How to Decide With Your Prescriber
• How Siggy Fits In
• The Bottom Line on Qelbree vs Strattera
• Start Your Anonymous Intake

How Qelbree and Strattera Work

Both drugs are FDA-approved for ADHD in adults and children 6 and older, and neither is a controlled substance.

Atomoxetine is a selective norepinephrine reuptake inhibitor, and our guide to how Strattera works covers it in depth.

Viloxazine adds activity at a serotonin receptor, though whether that changes how people feel on it is unproven. Overall, a 2026 viloxazine review found its effect sizes smaller than stimulants’ but comparable to atomoxetine’s.

Which Works Faster, Qelbree or Strattera?

The honest answer is that nobody has tested it directly. The same 2026 review noted that no head-to-head trials against atomoxetine have been run, apart from one small retrospective chart study.

In Qelbree’s adult phase 3 trial of 374 people, many treatment effects were already significant by week 2, and the average final dose was 504 mg. It was funded by Qelbree’s manufacturer, Supernus. A four-trial pediatric analysis found improvements in daily functioning as early as week 1 at 100 mg or week 2 at higher doses. A 2024 pediatric meta-analysis found that symptom improvement leveled off at around weeks 4 to 6.

Atomoxetine follows a longer curve. An atomoxetine response-trajectory review found it can start working within 1 to 2 weeks, with response continuing to build for up to 24 weeks or longer. Its authors were affiliated with the drug’s manufacturer.

Qelbree may reach its plateau sooner, but its placebo-controlled trials lasted only 6 to 8 weeks, so they can’t show whether it keeps building the way atomoxetine does. If you’re a few weeks in and unsure, talk with your prescriber before deciding it isn’t working.

How Dosing Differs

Qelbree is an extended-release capsule taken once a day, with or without food. Adults start at 200 mg and can increase by 200 mg each week to a maximum of 600 mg. Children 6 to 11 start at 100 mg and teens start at 200 mg, both with a maximum of 400 mg. The capsule can be swallowed whole or opened and sprinkled over applesauce or pudding, which helps if swallowing pills is hard.

The Strattera prescribing information starts adults, and children who weigh 70 kg or more, at 40 mg a day, raises the dose to a target of 80 mg after at least 3 days, and allows 100 mg if the response is still incomplete after 2 to 4 more weeks. Children under 70 kg are dosed by weight. Atomoxetine can be taken once in the morning or split into two doses, and the capsule must be swallowed whole.

Severe kidney impairment caps Qelbree at 200 mg, while atomoxetine’s dose is halved in moderate liver impairment and cut to a quarter in severe impairment.

The table below summarizes the main differences from each drug’s prescribing information and an FDA Federal Register notice on the brand’s status.

Feature	Qelbree (Viloxazine ER)	Strattera (Atomoxetine)
Adult Starting Dose	200 mg once daily	40 mg a day
Adult Maximum	600 mg	100 mg
Dose Increases	200 mg weekly	After 3+ days, then 2 to 4 weeks
Capsule Options	Whole or sprinkled	Swallow whole
Key Enzyme Issue	Strongly blocks CYP1A2	Cleared by CYP2D6
Form Sold Today	Brand-name Qelbree	Generic atomoxetine

Eli Lilly notified the FDA in 2025 that it was discontinuing brand-name Strattera, and the agency determined that the decision wasn’t made for safety or effectiveness reasons. Generic atomoxetine remains available.

Side Effects Compared

The side effects overlap, but the pattern differs. The labels report these rates for adults in placebo-controlled trials, and both caution that rates from separate trials can’t be directly compared.

Adult Side Effect	Qelbree	Strattera
Insomnia	23%	15%
Nausea	12%	26%
Dry Mouth	10%	20%
Decreased Appetite	10%	16%
Fatigue	12%	10%
Stopped for Side Effects	About 9%	11.3%

Qelbree’s adult data also showed headache in 17% of people versus 7% on placebo, and sleepiness in 6%. Atomoxetine’s adult trials added erectile dysfunction in 8% of men, urinary hesitation in 6%, and dizziness and constipation in 8% each. Our guide to Strattera side effects covers how those early effects tend to change over time.

If nausea hits, the atomoxetine label allows splitting the daily dose or taking it with food, options worth raising with your prescriber.

Drug Interactions Are the Biggest Practical Difference

This is where the two drugs part ways, especially if you also take an antidepressant. Our guide to ADHD and anxiety explains why those conditions so often overlap.

Atomoxetine is broken down by an enzyme called CYP2D6. Two common SSRIs, fluoxetine (Prozac) and paroxetine (Paxil), strongly block that enzyme. In the label’s studies, paroxetine raised atomoxetine exposure 6.5-fold and fluoxetine raised it 6- to 8-fold. The combination isn’t forbidden, but the label calls for a longer 4-week interval between dose increases. About 7% of White people, and about 2% of Black and Asian people, are genetic poor metabolizers who clear atomoxetine far more slowly and had higher heart rates and more side effects in trials.

Qelbree works the other way around. Viloxazine strongly blocks an enzyme called CYP1A2, so it can raise levels of drugs that depend on it. Its medication guide names six drugs that shouldn’t be taken with Qelbree: alosetron, duloxetine, ramelteon, tasimelteon, tizanidine, and theophylline. Duloxetine is Cymbalta, an SNRI antidepressant covered in our guide to Cymbalta for anxiety and depression. Viloxazine itself is only modestly affected by CYP2D6, with exposure about 21% to 26% higher in poor metabolizers.

Both drugs are off-limits with MAOI antidepressants and for 14 days after stopping one, so bring a full medication list to any appointment where either comes up.

Heart Rate, Mood, and Other Safety Warnings

Both drugs can raise heart rate and blood pressure. In adult trials, a heart rate jump of 20 beats per minute or more occurred at some point in 29% of people on Qelbree versus 13% on placebo, and in 22% on atomoxetine versus 8% on placebo. A cardiovascular network meta-analysis found that both drugs raised pulse and advised monitoring blood pressure and pulse with any ADHD medication, not only stimulants.

Both carry a boxed warning about suicidal thoughts and behaviors. For atomoxetine, the warning applies to children and teens. In pooled pediatric trials, 0.4% had suicidal thoughts versus none on placebo, and a similar analysis in adults didn’t find increased risk. Qelbree’s warning covers adults too. In its adult trial, 3 of 189 people (1.6%) reported suicidal thoughts versus none of 183 on placebo, and no suicide attempts occurred. Both labels advise screening for bipolar disorder, because either drug can trigger mania in people at risk.

Atomoxetine also carries warnings for rare but severe liver injury, urinary retention, and priapism. Qelbree can cause sleepiness that affects driving, and its label advises stopping it when pregnancy is recognized unless the benefits outweigh the risk.

If you notice new or worsening depression, agitation, or thoughts of harming yourself on either drug, contact your prescriber right away. In a crisis, call 911 or the 988 Suicide and Crisis Lifeline.

What Happens When People Switch?

The closest thing to a direct comparison is a chart review of 50 patients, most of them children, who switched from atomoxetine to Qelbree after a less-than-ideal response. By week 2, 86% reported a positive response on Qelbree, versus 14% on atomoxetine, and 36% had stopped atomoxetine for side effects, versus 4% who stopped Qelbree.

Those numbers are striking, but the study was retrospective and open-label, everyone took atomoxetine first, and insurers had required that generic trial before covering Qelbree. It suggests some people who struggle on atomoxetine do better on viloxazine, which is different from proving Qelbree is better for everyone.

How to Decide With Your Prescriber

The choice usually comes down to practical questions rather than which drug is stronger:

• Which antidepressants or other medications do you take now, or might take later?
• How much do nausea, sleep problems, or sexual side effects matter to you?
• Can you swallow capsules, or would sprinkle dosing help?
• How patient can you be with a gradual response, and what will your insurance cover?
• Do you have heart, liver, or kidney conditions your prescriber should weigh?

Our guide to guanfacine for ADHD covers another non-stimulant with a different mechanism.

How Siggy Fits In

Siggy’s care includes non-stimulant ADHD medications like Qelbree and atomoxetine, alongside treatment for anxiety and depression. A licensed prescriber reviews your intake and approves your plan before anything is prescribed.

That matters for the interaction questions above, because your ADHD and mood medications should be reviewed together. The anonymous intake needs no name, email, or account, and you’ll get a downloadable summary you can share with any clinician.

Siggy isn’t an emergency service. If you’re in crisis, call 911 or call or text 988. This article is for education only, so talk with your own clinician before starting, changing, or stopping any medication. It reflects sources available as of October 2026.

The Bottom Line on Qelbree vs Strattera

Qelbree and atomoxetine are more alike than different: both block norepinephrine reuptake, need weeks to show their full effect, and require heart rate and mood monitoring. The tradeoffs are sprinkle dosing and a faster-looking plateau for Qelbree against a generic option and a deeper adult evidence base for atomoxetine, with your other medications often settling the question. For a wider view of the options, see our guide to non-stimulant ADHD medications.

Start Your Anonymous Intake

If you’re in crisis right now, call 911 or call or text 988 first. If you’re weighing a non-stimulant and want your ADHD and mood medications looked at together, start your anonymous intake. It’s free, there’s no name or email required, and a licensed prescriber reviews your intake before anything is prescribed. Your summary is yours to keep and share with whoever helps you next.